Tebotelimab  (Synonyms: 特泊利单抗; MGD-013)

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity^[1][2][3].

[V-kappa'-VH-h-CH2-CH3_V-kappa-VH']2

Humanized

MGD013 (0.39, 1.56, 6.25, 25 nM; 48 小时) 增强人 PBMC 中 T 细胞抗原受体驱动的激活。与 PD-1 + LAG-3 mAb 组合相比，MGD013 显示增强的葡萄球菌肠毒素 B (SEB; 0.5mg/mL) 诱导 IFN-γ 分泌^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2245725-04-4

液体

Colorless to light yellow

特泊利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [V-kappa'-VH-h-CH2-CH3_V-kappa-VH']2

• 
  Immobilized Tebotelimab can bind Human PD-1 Protein (ECD, His Tag). The EC₅₀ for this effect is 0.413 ng/mL.
• 
  Immobilized Tebotelimab can bind Human LAG-3 Protein (ECD, His Tag). The EC₅₀ for this effect is 0.423 ng/mL.

• [1]. Ross LaMotte-Mohs, et al. Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. Cancer Res (2016) 76 (14_Supplement): 3217.

  [2]. Daniel Vt Catenacci, et al.MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Apr;17(10):1155-1164.  [Content Brief]

  [3]. Yiming Wei, et al. LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance. Front Oncol. 2022 Apr 14;12:831407.  [Content Brief]